Search results for " T-Cell"

showing 10 items of 320 documents

Analysis of TCR Vbeta repertoire and cytokine gene expression in patients with idiopathic dilated cardiomyopathy

2001

Although the etiopathogenesis of idiopathic dilated cardiomyopathy (IDC) is still unclear, it is widely accepted that a complex interplay between viral infections and immune mechanisms is the basis of disease genesis. Previously, we showed that heart-infiltrating T cells of patients suffering from acute, fulminant Coxsackie virus B3+-IDC shared a preferential usage of three variable gene segments of the T cell receptor beta chain-(TCR-Vbeta) encoding families Vbeta3, 7 and 13.1. This indicated the possible presence of a superantigen-driven immune response. Here, we further investigated the IDC immunological scenario by analysing different phenotypes of heart-infiltrating cells: TCR repertoi…

Cardiomyopathy DilatedInterleukin 2MyocarditisCD8 AntigensReceptors Antigen T-Cell alpha-betaT cellImmunologyCardiomyopathyGene Expressionchemical and pharmacologic phenomenaPicornaviridaeBiologyHLA-DQ alpha-ChainsImmunoenzyme TechniquesInterferon-gammaImmune systemAntigenHLA-DQ AntigensIdiopathic dilated cardiomyopathymedicineHLA-DQ beta-ChainsHumansImmunology and AllergyRNA MessengerAntigens ViralInterleukin-6Reverse Transcriptase Polymerase Chain ReactionHistocompatibility TestingMyocardiumIDC cytokines immune mechanismsmedicine.diseaseEnterovirus B HumanMyocarditismedicine.anatomical_structureCD4 AntigensImmunologyLeukocytes MononuclearCytokinesInterleukin-2Interleukin-4CD8Interleukin-1medicine.drug
researchProduct

Invariant natural killer T cells act as an extravascular cytotoxic barrier for joint-invading Lyme Borrelia

2014

CXCR6-GFP(+) cells, which encompass 70% invariant natural killer T cells (iNKT cells), have been found primarily patrolling inside blood vessels in the liver. Although the iNKT cells fail to interact with live pathogens, they do respond to bacterial glycolipids presented by CD1d on liver macrophage that have caught the microbe. In contrast, in this study using dual laser multichannel spinning-disk intravital microscopy of joints, the CXCR6-GFP, which also made up 60-70% iNKT cells, were not found in the vasculature but rather closely apposed to and surrounding the outside of blood vessels, and to a lesser extent throughout the extravascular space. These iNKT cells also differed in behavior,…

CellMice TransgenicSpleenjoint iNKT cellsGranzymesMicegranzyme BmedicineAnimalsHumansCytotoxic T cellBorrelia burgdorferiImmunity CellularLyme DiseaseMice Inbred BALB CMultidisciplinarybiologyLyme arthritisNatural killer T cellbiology.organism_classificationGranzyme Bmedicine.anatomical_structureLiverGranzymeOrgan SpecificityBorrelia burgdorferiCD1DImmunologybiology.proteinNatural Killer T-CellsJointsJoint DiseasesSpleen
researchProduct

Th9 cells, new players in adaptive immunity.

2014

Upon antigen-specific stimulation, naive CD4⁺ T cells have the potential to differentiate into various T helper (Th) cell subsets. Earlier models of Th cell differentiation focused on IFN-γ-producing Th1 cells and IL-4-secreting Th2 cells. The discovery of additional CD4⁺ Th cell subsets has extended our understanding of Th cell differentiation beyond this dichotomy. Among these is the recently described Th9 cell subset, which preferentially produces interleukin (IL)-9. Here, we review the latest developments in Th9 cell development and differentiation, focusing on contributing environmental signals, and discuss potential physiological and pathophysiological functions of these cells. We des…

Cellular differentiationImmunologyReceptors Antigen T-CellAdaptive ImmunityMiceT-Lymphocyte SubsetsTransforming Growth Factor betaNeoplasmsmedicineHypersensitivityImmunology and AllergyAnimalsHumansInterleukin 9Interleukin 4biologyCell growthLymphocyte differentiationInterleukin-9Models ImmunologicalReceptors Interleukin-2Transforming growth factor betaT helper cellT-Lymphocytes Helper-InducerAcquired immune systemReceptors Interleukin-4medicine.anatomical_structureImmunologyInterferon Regulatory Factorsbiology.proteinSignal TransductionTrends in immunology
researchProduct

Stimulation of synovial fluid mononuclear cells with the human 65-kD heat shock protein or with live enterobacteria leads to preferential expansion o…

1992

SUMMARY T lymphocyte responses to heterologous or self 65-kD heat shock protein (hsp) have been implicated in the pathogenesis of various forms of arthritis. To delineate the relationship of 65-kD hsp to different synovial fluid (SF) T cell subsets, we stimulated synovial fluid (SFMC) and peripheral blood mononuclear cells (PBMC) from patients with different inflammatory rheumatic diseases and from healthy controls with human or mycobacterial 65-kD hsp, tetanus toxoid (TT), heat-killed or live Yersinia enterocotitica. Phenotyping of the resulting T cell lines revealed an increase of up to 97% TCR-γδ+ lymphocytes in the 65-kD hsp-stimulatcd SF-derived lines. This expansion of TCR-γδ+ cells w…

Cellular immunityT cellReceptors Antigen T-Cell alpha-betaT-LymphocytesImmunologyBiologyYersiniaLymphocyte ActivationPeripheral blood mononuclear cellMonocytesCell LineAntigenEnterobacteriaceaeHeat shock proteinSynovial FluidmedicineImmunology and AllergySynovial fluidHumansHeat-Shock ProteinsReceptors Antigen T-Cell gamma-deltaT lymphocytebiology.organism_classificationClone Cellsmedicine.anatomical_structurePhenotypeImmunologyResearch Article
researchProduct

NF-κB inducing kinase (NIK) is an essential post-transcriptional regulator of T-cell activation affecting F-actin dynamics and TCR signaling

2018

NF-κB inducing kinase (NIK) is the key protein of the non-canonical NF-κB pathway and is important for the development of lymph nodes and other secondary immune organs. We elucidated the specific role of NIK in T cells using T-cell specific NIK-deficient (NIKΔT) mice. Despite showing normal development of lymphoid organs, NIKΔT mice were resistant to induction of CNS autoimmunity. T cells from NIKΔT mice were deficient in late priming, failed to up-regulate T-bet and to transmigrate into the CNS. Proteomic analysis of activated NIK-/- T cells showed de-regulated expression of proteins involved in the formation of the immunological synapse: in particular, proteins involved in cytoskeleton dy…

Central Nervous System0301 basic medicineEncephalomyelitis Autoimmune ExperimentalT-LymphocytesT cellPrimary Cell CultureImmunologyReceptors Antigen T-CellPriming (immunology)Protein Serine-Threonine KinasesBiologyLymphocyte ActivationImmunological synapseMice03 medical and health sciences0302 clinical medicineImmune systemmedicineAnimalsImmunology and AllergyProtein kinase BAdaptor Proteins Signal TransducingMice KnockoutMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3ZAP-70 Protein-Tyrosine KinasePhospholipase C gammaGene Expression ProfilingZAP70T-cell receptorMembrane ProteinsPhosphoproteinsActinsPeptide FragmentsCell biologyMice Inbred C57BL030104 developmental biologymedicine.anatomical_structureGene Expression Regulation030220 oncology & carcinogenesisMyelin-Oligodendrocyte GlycoproteinLymph NodesSignal transductionT-Box Domain ProteinsProto-Oncogene Proteins c-aktSpleenSignal TransductionJournal of Autoimmunity
researchProduct

Different T-cell Receptor (TCR) Zeta Chain Expression in Cervical Cancer and its Precursor Lesions

2006

OBJECTIVE Cervical cancer is associated with infection of epithelial cells with the human papillomavirus (HPV) type 16 and HPV18. A functional signalling machinery in T-cells is required in order to successfully fight and eradicate HPV16+ transformed epithelial cells. One of the key signalling molecules associated with the T-cell receptor (TCR) is the homodimeric zeta chain molecule. MATERIAL AND METHODS 28 formalin fixed und paraffin embedded samples of cervical tissue with cervical intraepithelial lesions CIN I (n = 3), CIN III (n = 7), invasive cervical carcinoma (CC) (n = 13) and normal cervical tissue (n = 5) has been evaluated for HPV-PCR und zeta chain immunohistochemistry. For immun…

Cervical cancerPathologymedicine.medical_specialtybusiness.industrymedicine.drug_classT-cell receptorReceptors Antigen T-CellMembrane ProteinsUterine Cervical NeoplasmsObstetrics and GynecologyCancerUterine Cervical Dysplasiamedicine.diseaseMonoclonal antibodyPeripheral blood mononuclear cellMolecular biologyMonoclonalmedicineHumansImmunohistochemistryFemaleNeoplasm InvasivenessClone (B-cell biology)businessZentralblatt für Gynäkologie
researchProduct

Teaming up for CAR-T cell therapy

2019

Adoptive cellular therapy using chimeric antigen receptor T-cell (CART) therapy is currently being evaluated in patients with relapsed / refractory multiple myeloma (MM). The majority of CAR-T cell programs now being tested in clinical trials are targeting B-cell maturation antigen. Several recent phase I / II trials show promising preliminary results in patients with MM progressing on proteasome inhibitors, immunomodulatory drugs and monoclonal antibodies targeting CD38. CAR-T cell therapy is a potentially life-threatening strategy that can only be administered in experienced centers. For the moment, CAR-T cell therapy for MM is still experimental, but once this strategy has been approved …

Consensusbusiness.industrymedicine.medical_treatmentHematologyImmunotherapymedicine.diseaseImmunotherapy AdoptiveEuropeEditorialPractice Guidelines as TopicCancer researchmedicineCAR T-cell therapyHumansReceptorbusinessMultiple MyelomaMultiple myelomaSocieties Medical
researchProduct

Cutting edge: priming of CTL by transcutaneous peptide immunization with imiquimod.

2005

Abstract CTL are important in combating cancer and viruses. Therefore, triggering the complete potential of CTL effector functions by new vaccination strategies will not only improve prophylaxis of tumor or virus-related diseases, but also open opportunities for effective therapeutic immunizations. Using transcutaneous immunization, we show that epicutaneous (e.c.)4 application of an ointment containing a CTL epitope and the TLR7 ligand imiquimod is highly effective in activating T cells in mice using TCR-transgenic CTL or in wild-type mice. Transcutaneous immunization-activated CTL mount a full-blown immune response against the target epitope characterized by proliferation, cytolytic activ…

Cytotoxicity ImmunologicAdoptive cell transferImmunologyReceptors Antigen T-CellPriming (immunology)Epitopes T-Lymphocytechemical and pharmacologic phenomenaImiquimodMice TransgenicAdministration CutaneousLymphocyte ActivationResting Phase Cell CycleEpitopeMiceImmune systemmedicineImmunology and AllergyAnimalsCells CulturedMice KnockoutImiquimodbusiness.industryTLR7VirologyAdoptive TransferVaccinationMice Inbred C57BLCTL*Protein TransportImmunologyVaccines SubunitAminoquinolinesLymph NodesbusinessSpleenmedicine.drugT-Lymphocytes CytotoxicJournal of immunology (Baltimore, Md. : 1950)
researchProduct

T cells engineered to express a T-cell receptor specific for glypican-3 to recognize and kill hepatoma cells in vitro and in mice

2015

Background & Aims Cancer therapies are being developed based on our ability to direct T cells against tumor antigens. Glypican-3 (GPC3) is expressed by 75% of all hepatocellular carcinomas (HCC), but not in healthy liver tissue or other organs. We aimed to generate T cells with GPC3-specific receptors that recognize HCC and used them to eliminate GPC3-expressing xenograft tumors grown from human HCC cells in mice. Methods We used mass spectrometry to obtain a comprehensive peptidome from GPC3-expressing hepatoma cells after immune-affinity purification of human leukocyte antigen (HLA)-A2 and bioinformatics to identify immunodominant peptides. To circumvent GPC3 tolerance resulting from feta…

Cytotoxicity ImmunologicCancer Immunotherapy ; Immune Response ; Liver Cancer ; Tumor-associated AntigensCarcinoma HepatocellularTime FactorsCell SurvivalMice SCIDCD8-Positive T-LymphocytesBiologyLymphocyte ActivationTransfectionImmunotherapy AdoptiveInterferon-gammaInterleukin 21GlypicansHLA-A2 AntigenAnimalsHumansCytotoxic T cellIL-2 receptorAntigen-presenting cellInterleukin 3HepatologyImmunodominant EpitopesZAP70Liver NeoplasmsGastroenterologyDendritic CellsHep G2 CellsNatural killer T cellXenograft Model Antitumor AssaysMolecular biologyCoculture TechniquesGenes T-Cell ReceptorInterleukin 12FemaleGenetic Engineering
researchProduct

Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia

2021

BackgroundT-cell acute lymphoblastic leukemia (T-ALL) is an aggressive disease with a poor cure rate for relapsed/resistant patients. Due to the lack of T-cell restricted targetable antigens, effective immune-therapeutics are not presently available and the treatment of chemo-refractory T-ALL is still an unmet clinical need. To develop novel immune-therapy for T-ALL, we generated an afucosylated monoclonal antibody (mAb) (ahuUMG1) and two different bispecific T-cell engagers (BTCEs) against UMG1, a unique CD43-epitope highly and selectively expressed by T-ALL cells from pediatric and adult patients.MethodsUMG1 expression was assessed by immunohistochemistry (IHC) on a wide panel of normal t…

Cytotoxicity ImmunologicCancer Research2434T-LymphocytesMice SCIDafucosylated monoclonal antibodyLymphocyte ActivationPrecursor T-Cell Lymphoblastic Leukemia-LymphomaEpitopesJurkat CellsAntineoplastic Agents ImmunologicalAntibody SpecificityMice Inbred NODantigensAntibodies BispecificTumor MicroenvironmentImmunology and Allergyantibodieshematologic neoplasms1506RC254-282Antibody-dependent cell-mediated cytotoxicityLeukosialinbispecific T-cell engagersmedicine.diagnostic_testbiologyhematological malignancieNeoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.anatomical_structureantibodieOncologytranslational medical researchMolecular MedicineImmunohistochemistryFemaleimmunotherapyAntibodyT-ALLT-cell engagersT-cell acute lymphoblastic leukemiamedicine.drug_classT cellImmunologySettore MED/08 - Anatomia PatologicaMonoclonal antibodyAntibodies Monoclonal HumanizedFlow cytometryT Acute Lymphoblastic LeukemiaantigenAntigenPhagocytosismedicineAnimalsHumanshematological malignanciesCell ProliferationPharmacologyT-cell engagerbusiness.industryhematological malignancies; antibodies; antigens; hematologic neoplasms; immunotherapy; neoplasm; T-ALL; T-cell engagers; translational medical research; translational researchBasic Tumor ImmunologyXenograft Model Antitumor Assaystranslational researchCancer researchbiology.proteinneoplasmbusinesshematologic neoplasmneoplasm
researchProduct